Condition: Advanced/Metastatic Colorectal Adenocarcinoma · Sponsor: Bayer
Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS. Colorectal cancer (CRC) is a common type of cancer that affects the large bowel (colon) or the rectum (the section at the end of the bowel). When CRC spreads to other parts of the body, it is called advanced or metastatic CRC. Some people with CRC have the G12D mutation in the KRAS protein. This mutation is linked to a poorer outlook and fewer treatment options. Currently, there are no approved treatments that specifically target this mutation. KRAS is a protein that helps control how cells grow and divide. When it is mutated, it can cause cells to grow uncontrollably, leading to cancer. The study drug, BAY 3771249, is designed to block the activity of KRAS with G12D mutation, which may help slow or stop the growth of cancer cells. BAY 3771249 can be given alone or together with another drug called cetuximab. The main purpose of this study is to learn how safe BAY 3771249 is, how well people tolerate it, how the body processes the drug, and whether it can help shrink or control tumors in people with advanced or metastatic CRC that has the KRAS G12D mutation. The study will also look at how BAY 3771249 works when given alone or with cetuximab, especially in people who have already tried other treatments for their cancer. Researchers will measure, among others: The number and seriousness of h…
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic - Cancer Center - Phoenix | Phoenix, Arizona, United States | Not Yet Recruiting |
| City of Hope - Duarte Cancer Center | Duarte, California, United States | Not Yet Recruiting |
| UC San Diego Health - Moores Cancer Center | San Diego, California, United States | Not Yet Recruiting |
| Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's | Denver, Colorado, United States | Not Yet Recruiting |
| Icahn School of Medicine at Mount Sinai - Oncology | New York, New York, United States | Not Yet Recruiting |
| NEXT Dallas - Oncology Department | Irving, Texas, United States | Recruiting |
| START | San Antonio | San Antonio, Texas, United States | Not Yet Recruiting |
| Border Medical oncology - Albury Wodonga Regional Cancer Centre | Albury, New South Wales, Australia | Not Yet Recruiting |
| Calvary Mater Hospital Newcastle - Oncology | Waratah, New South Wales, Australia | Recruiting |
| Cabrini Health Oncology Research | Malvern, Victoria, Australia | Not Yet Recruiting |
| Ghent University Hospital | Drug Research Unit Department | Ghent, Belgium | Not Yet Recruiting |
| Rigshospitalet - Kræftbehandling | Copenhagen, Capital Region, Denmark | Not Yet Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07535112